Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)
• Progression of disease during platinum-based (cisplatin or carboplatin) chemotherapy or within 3 months of completing chemotherapy
• * Treatment with other agents since prior platinum-based chemotherapy allowed
• Measurable disease
• * Target lesions within a prior radiation field must have documented evidence of progression at least 8 weeks after the completion of radiotherapy
• No active brain or leptomeningeal metastases
• * Treated brain metastases allowed at least 4 weeks after the completion of appropriate therapy
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hemoglobin at least 8 g/dL
• Hepatic
• Bilirubin no greater than upper limit of normal (ULN)
• AST/ALT no greater than 2.5 times ULN (if alkaline phosphatase is no greater than ULN)
• Alkaline phosphatase no greater than 5 times ULN (if AST and ALT are greater than ULN)
• No history of chronic hepatitis
• Renal
• Creatinine no greater than 1.5 times ULN
• Cardiovascular
• No active thromboembolic event within the past 4 weeks
• No uncontrolled congestive heart failure
• No uncontrolled angina
• No myocardial infarction and/or stroke within the past 6 months
• Pulmonary
• No evidence of clinically active interstitial lung disease
• Gastrointestinal
• No history of gastrointestinal bleeding within the past 6 months
• No history of peptic ulcer disease
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Must weigh at least 110 pounds (50 kg)
• HIV negative
• No allergy to sulfonamides
• No allergy to any NSAID, including celecoxib
• No known severe hypersensitivity to gefitinib or any of its excipients
• No other malignancy within the past 3 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
• No history of dementia, active psychiatric disorder, or any other condition that would preclude study compliance
• No other concurrent serious medical condition
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No prior epidermal growth factor receptor inhibitor
• No concurrent biologic therapy
• Chemotherapy
• See Disease Characteristics
• More than 2 weeks since prior chemotherapy
• Endocrine therapy
• Not specified
• Radiotherapy
• Recovered from prior radiotherapy
• Surgery
• Recovered from prior surgery
• Other
• Recovered from prior therapy
• More than 2 weeks since prior investigational therapy
• More than 1 week since prior fluconazole
• More than 30 days since prior participation in another investigational agent clinical trial
• More than 30 days since prior chronic nonsteroidal anti-inflammatory drugs (NSAIDs), including celecoxib or rofecoxib
• No prior gefitinib
• No prior cyclooxygenase-2 (COX-2) inhibitor or another clinical trial for NSCLC
• No other concurrent NSAIDs
• * Concurrent aspirin allowed (not to exceed 325 mg/day)
• No other concurrent COX-2 inhibitors
• No concurrent lithium
• No concurrent fluconazole
• No concurrent use of any of the following:
• * Phenytoin
• * Carbamazepine
• * Barbiturates
• * Rifampin
• * Phenobarbital
• * Hypericum perforatum